DEVELOPMENT CENTER FOR BIOTECHNOLOGY Patent applications |
Patent application number | Title | Published |
20160136176 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS - The present invention relates to pyrimidine compounds of formula (I): | 05-19-2016 |
20160130336 | ANTI-VEGF ANTIBODIES AND USE THEREOF - An anti-VEGF antibody, or a binding fragment thereof, includes a heavy-chain variable region that comprises: (1) a CDRH1 sequence selected from SEQ ID NO: 17, 20, 23, 26, 29, 32, 35, or 38), (2) a CDRH2 sequence selected from SEQ ID NO:18, 21, 24, 27, 30, 33, 36, or 39, and (3) a CDRH3 sequence selected from SEQ ID NO:19, 22, 25, 28, 31, 34, 37, or 40; and a light-chain variable region that comprises: (1) a CDRL1 sequence selected from SEQ ID NO: 41, 44, 47, 50, 53, 56, 59, or 62, (2) a CDRL2 sequence selected from SEQ ID NO: 42, 45, 48, 51, 54, 57, 60, or 63, and (3) a CDRL3 sequence selected from SEQ ID NO: 43, 46, 49, 52, 55, 58, 61, or 64. A method for treating or preventing a VEGF-related disorder, e.g., diabetic retinopathy, age-related macular degeneration, or cancer, uses the antibodies. | 05-12-2016 |
20150183884 | ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY - The present invention discloses an anti-human alpha-enolase (ENO1) antibody, which can bind the peptides, comprising amino-acid sequence 296FD Q D D W G A W Q K F TA309 (SEQ ID: #9) and/or 326K R I A K A V N EK S336 (SEQ ID: #10) of human ENO1 protein (GenBank: AAH50642.1), has a favorable binding activity (the binding affinity is around 2.19×10-10 mol/L) and a remarkable capability to inhibit the cell invasion and tumor metastasis of a varied of tumors. The recognized peptides and antibody of the invention are useful for diagnosis, prognosis, and treatment of cancers that have been reported to express cell-surface ENO1 such as including lung, breast, pancreas, liver, colorectal, prostate cancers and solid tumors. | 07-02-2015 |
20150182572 | PLANT EXTRACT AND THE PROCESS FOR TREATING HEPATIC FIBROSIS AND LIVER CANCER - An extract of | 07-02-2015 |
20150158854 | QUINAZOLINE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF - A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) | 06-11-2015 |
20140363372 | METHODS FOR SUPPRESSING CANCER BY INHIBITION OF TMCC3 - A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample. | 12-11-2014 |
20140186352 | ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE THEREOF - An anti-granulysin antibody, or an scFv or Fab fragment thereof, capable of binding to an epitope region from R64 to R113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of SEQ ID NO:82 to SEQ ID NO:195, or the antibody may contain a sequence selected from the sequences of SEQ ID NO:39 to SEQ ID NO:76. The antibody may be a monoclonal antibody. A method for treating or preventing an unwanted immune response disorder includes administering to a subject in need thereof an effective amount of an anti-granulysin antibody capable of neutralizing the activity of granulysin. The unwanted immune response disorder may be SJS, TEN, or GVHD. | 07-03-2014 |
20140178360 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS - The present invention relates to pyrimidine compounds of formula (I): | 06-26-2014 |
20130331323 | GLP-1 POTENTIATORS FROM HEDYCHIUM CORONARIUM AND THEIR APPLICATIONS - A compound for controlling blood glucose level has a structure shown in Formula I: | 12-12-2013 |
20130309337 | PROCESS FOR THE PREPARATION OF PLANT EXTRACTS FOR TREATING SKIN DISORDERS AND ENHANCING HEALING OF WOUNDS - The present invention provides a process for the preparation of | 11-21-2013 |
20130274255 | HETEROCYCLIC PYRAZOLE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF - The present invention relates to a compound of formula (I): | 10-17-2013 |
20130165638 | LIGHT CHAIN-BRIDGED BISPECIFIC ANTIBODY - This invention describes a novel format of monomeric bispecific fusion protein with immune activating property for clinical therapies. A bispecific fusion protein includes a first targeting domain with a specificity for a first target of interest; a bridging domain derived from a constant region of a light chain or heavy chain of an immunoglobulin, which may be a human immunoglobulin; and a second targeting domain with a specificity for a second target of interest. The bispecific fusion protein may further include a linker fused to the N-terminus or the C-terminus of the bridging domain. The first targeting domain is fused to the bridging domain and the second targeting domain is fused to the bridging domain or the linker. The linker may include a GGGGS sequence. The first target of interest may be CD | 06-27-2013 |
20130165629 | BISPECIFIC T-CELL ACTIVATOR ANTIBODY - This invention relates to bispecific antibodies having combinations of linker and hinge sequences to create linker-hinge interface domains with biological significance. Such linker-hinge interface domains covalently join two molecules, maintain the biological activities of linked molecules (target binding), stabilize the biological characteristics of new molecule (solubility and 4° C. stability), maintain the chemical, biochemical and physical properties (cytotoxicity) of the linked molecules, and modulate the biological characteristics of the linked molecules (activating T-lymphocytes without significant sign of proliferations). Both linker (GGGGS) and hinge (CPPCP) sequences are required to establish functional linker-hinge interface domains as deletion of any of the component resulted in significant lost of T-lymphocyte mediated activity. | 06-27-2013 |
20130165458 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS - A compound for treating protein kinase-related disease or disorder having a structure of formula (A): | 06-27-2013 |
20130040004 | PLANT EXTRACT FOR TREATING DIABETES AND PROCESS FOR MAKING SAME - The present invention relates to a plant extract for treating diabetes and a process for making same. The plant extract of the invention is prepared from an overground part of | 02-14-2013 |
20120288492 | NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS - The present invention relates to pyrimidine compounds of formula (I): | 11-15-2012 |
20120172374 | NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME - Compounds represented by the formula (I) or pharmaceutically acceptable salts thereof: | 07-05-2012 |
20120114678 | TREATMENT FOR NEPHRITIS - This invention relates to methods for treatment of nephritis. This invention further provides a method of treating with nephritis comprising administering to the subject an amount of herbal pharmaceutical composition thereof effective to treat the subject. Move particularly, this invention provides an herbal pharmaceutical composition comprising Rhizoma | 05-10-2012 |
20110236424 | TREATING ALLERGY WITH DETOXIFIED E. COLI HEAT-LABILE ENTEROTOXIN - A method for treating allergy with a pharmaceutical composition containing a detoxified | 09-29-2011 |
20110195139 | USE OF OVERGROUND PART OF HEDYCHIUM CORONARIUM KOENIG IN REDUCING BLOOD GLUCOSE; EXTRACTS AND COMPOSITIONS OF OVERGROUND PART OF HEDYCHIUM CORONARIUM KOENIG AND THEIR USES - The present invention is related to the use of an overground part of | 08-11-2011 |
20100152226 | SUSTAINED RELEASE IMPLANT FOR GRANISETRON - The main goals of the invention are to develop the long-term release of Granisetron injection implant composition with biodegradable polymer and to develop relative processing. Granisetron is mixed with different biodegradable polymers, and then hot melt extrusion technique with different diameter, temperature, rate of extrusion and holding time is applied to make implant. In vitro dissolution of the Granisetron injection implant composition shows the component continued release of the drug for over 7 days. | 06-17-2010 |
20090324751 | CHINESE HERB EXTRACT FOR TREATING DEMENTIA AND PREPARATION METHOD THEREOF - The present invention relates to a | 12-31-2009 |
20090120808 | Device for Detecting Methanol Concentration and the Method Thereof - A device for detecting methanol concentration in an alcohol-containing solution is disclosed. The device implements an electrochemical bio-detector based on a two-enzyme system to quickly, easily and accurately measure methanol concentration in an alcohol-containing solution at a relatively low cost. A method for detecting methanol concentration in a sample using the same device is also disclosed. | 05-14-2009 |
20090060985 | PROCESS FOR THE PREPARATION OF PLANT EXTRACTS FOR TREATING SKIN DISORDERS AND ENHANCING HEALING OF WOUNDS - The present invention provides a process for the preparation of | 03-05-2009 |
20080220519 | MUTATED E. COLI HEAT-LABILE ENTEROTOXIN - This invention relates to a mutant | 09-11-2008 |